Soluble ST2-Analytical Considerations
Soluble ST2-Analytical Considerations
复制标题
DOI：
10.1016/j.amjcard.2015.01.035
复制
发表时间：
2015-04-02
影响因子：
2.8
通讯作者：
Jaffe, Allan S.
中科院分区：
文献类型：
--
作者：
Mueller, Thomas;Jaffe, Allan S.
肿瘤发生抑制2（ST 2，也称为白细胞介素[WI-1受体样-1]）是IL-1受体家族成员，具有跨膜（ST 2L）和可溶性同种型（sST 2）。ST 2L是一种膜结合受体，IL-33是ST 2L的功能性配体。sST 2是ST 2L的可溶性截短形式，分泌到循环中并作为IL-33的“诱饵”受体发挥作用，抑制IL-33/ST 2L信号传导。sST 2的血液浓度在炎症性疾病和心脏病中增加，并且被认为是这两种疾病中有价值的预后标志物。在多项临床试验中，sST 2已成为心脏病患者临床上有用的预后生物标志物。有趣的是，sST 2甚至在低风险社区人群中提供预后信息。在这篇综述中，我们将讨论测量循环sST 2的分析考虑因素，包括分析前的问题，如sST 2的体外稳定性，sST 2的生物学变异，和分析后的问题，如参考范围和与患病队列的比较。(C)2015 Elsevier Inc. All rights reserved.
Suppression of tumorigenicity 2 (ST2, also known as interleukin [WI-1 receptor-like-1) is an IL-1 receptor family member with transmembrane (ST2L) and soluble isoforms (sST2). ST2L is a membrane-bound receptor, and IL-33 is the functional ligand for ST2L. sST2, a soluble truncated form of ST2L, is secreted into the circulation and functions as a "decoy" receptor for IL-33, inhibiting IL-33/ST2L signaling. Blood concentrations of sST2 are increased in inflammatory diseases and heart disease and are considered a valuable prognostic marker in both conditions. In multiple clinical trials, sST2 has emerged as a clinically useful prognostic biomarker in patients with cardiac diseases. Interestingly, sST2 even provides prognostic information in low-risk community-based populations. In this review, we will discuss analytical considerations of measuring circulating sST2 including pre-analytical issues, such as in vitro stability of sST2, biological variation of sST2, and postanalytical issues, such as reference ranges and comparisons to diseased cohorts. (C) 2015 Elsevier Inc. All rights reserved.